Abstract:OBJECTIVE To establish a serum-free culture system of dendritic cells (DCs) from chronic myeloid leukemia (CML) cells so that DCs vaccine may be applied to the adoptive immunotherapy of CML in the near future. METHODS Fetal calf serum, serum-free medium and autologous serum were used for culture of DCs. The usage of cytokines was classified into two groups: group A (stem cell factor, granulocyte/macrophage colony-stimulating-factor, tumor necrosis factor-alpha and interleukin-4) and group B (granulocyte/macrophage colony-stimulating-factor, tumor necrosis factor-alpha and interleukin-4). The phenotypes of DCs were analyzed by using indirect immunofluorescence and flow cytometry. Mixed leukocyte responses were performed by methyl thiazolyl tetrazolium (MTT) assay. Chromosome analysis of DCs can be achieved by displaying G banding. T cells from CML patients were stimulated with autologous DCs and T-cell cytotoxicity was measured by (MTT) assay. RESULTS CD34(+) cells or mononuclear cells were obtained from peripheral blood or bone marrow samples of eight patients of chronic-phase CML. Group A of serum-free medium was better than group B in expansion of total cell numbers and the rate of DCs. These results of serum-free medium were not significantly different from those of fetal calf serum medium, but the results of autologous serum medium were inferior to two groups above. The expression of major histocompatibility complex class II antigen on the surface of DCs was notable (> 50%), but the expression of CD83 and the costimulatory molecules CD86 was not noticeable (10% - 50%). Although CD1a(+)/CD14(-) DCs were potent stimulators of allogeneic lymphocytes, expansion of T cells from normal volunteers were not significant (average 27.2 fold at DCs: T cells ratio of 1:10). At day 12, CD1a(+) cells from three patients were studied by displaying G banding and Ph(+) cells in these populations were 100%, 98% and 60%, respectively. At an effector: target ratio of 40:1, 32% to 45% cytotoxicity was noted with DC-stimulated T cells against autologous leukemia cells. CONCLUSIONS A stable serum-free culture system of CML-DCs was established. The expression of CD83 and CD86 on the surface of CML-DCs and DCs' potent stimulation of allogeneic lymphocytes were not notable. DCs in CML patients can be derived from the malignant clone and these malignant DCs could induce anti-leukemic reactivity in autologous T lymphocytes without the necessity for additional exogenous antigens.

Presentation about Dendritic Cell Vaccine Loaded Different Antigens from Chronic Myeloid Leukemia

Progress on Dendritic Cell Vaccines in Tumor Immunotherapy

The study of dendritic cells derived from acute myeloid leukemia cells]

[Biological features of dendritic cells derived from chronic myeloid leukemia cells in vitro].

Induction of dendritic cells with IFN-alpha and GM-CSF from bone marrow mononuclear cells from patients with chronic myeloid leukemia

The Induction of Dendritic Cells with Ifn-Alpha and Gm-Csf from Bone Marrow Mononuclear Cells from Patients with Chronic Myeloid Leukemia.

The Biological Characteristics of Dendritic Cells Derived in Vitro from Myelogeneous Leukemia Cells and Healthy Donor Cells.

The Immunomodulatory Effects of Cordyceps Sinensis on Dendritic Cells Derived from Chronic Myelogenous Leukemia (Cml)

Expansion in Vitro and Cytotoxicity of Dendritic Cells from Patients with Chronic Myeloid Leukemia.

Study On Specific Anti-Leukemia Function Of Dendritic Cells (Dc) Vaccine Induced From Chronic Myeloid Leukemia (Cml)

[The Function of Dendritic Cells Derived from Chronic Myeloid Leukemia]

Differentiation of Chronic Myeloid Leukemia Cells to Dendritic Cells Induced by Interferon Α and Granulocyte-Macrophage Colony-Stimulating Factor

Serum-free Culture of Dendritic Cells from Patients with Chronic Myeloid Leukemia in Vitro and Estimation of Their Cytotoxicity

In vitro investigation on specific anti-myeloma activity of the glycoengineering modified dendritic cell vaccine

Inducing Large Numbers of Dendritic Cells from Primary Cells of Chronic Myeloid Leukemia and the Function Research

Specific Cell Immune Response Mediated by Myeloma Lysate Pulsed Dendritic Cells

Immune Responses of Dendritic Cells Plused with Myeloma Antigen

Combined Rhgm-Csf and Rhil-4 in Induction of Dendritic Cells Derived from Chronic Myeloid Leukemia Cells

Research of Dendritic Cells from Human Peripheral Blood in Vitro Loaded with Different Colorectal Carcinoma Cells Lysate Antigen

[Killing effect of cytotoxicty T lymphocyte primed by two different methods preparation of dendritic cells pulsed with antigen on Tca8113 cells in vitro].

Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells.